Galapagos NV
Index- P/E- EPS (ttm)-3.06 Insider Own- Shs Outstand65.55M Perf Week0.42%
Market Cap3.80B Forward P/E- EPS next Y-3.25 Insider Trans- Shs Float40.05M Perf Month-10.61%
Income- PEG- EPS next Q-0.88 Inst Own16.22% Short Float1.59% Perf Quarter-13.19%
Sales526.20M P/S7.22 EPS this Y45.70% Inst Trans- Short Ratio1.95 Perf Half Y9.81%
Book/sh39.94 P/B1.45 EPS next Y-5.90% ROA- Target Price73.67 Perf Year-22.60%
Cash/sh- P/C- EPS next 5Y0.71% ROE- 52W Range46.41 - 81.12 Perf YTD5.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-28.54% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low24.91% ATR2.08
Employees1319 Current Ratio- Sales Q/Q-49.70% Oper. Margin- RSI (14)41.42 Volatility2.72% 3.20%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.73 Prev Close58.83
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume325.69K Price57.97
Recom2.60 SMA20-4.10% SMA50-7.28% SMA2000.34% Volume563,593 Change-1.46%
Jan-27-22Upgrade Citigroup Neutral → Buy
Aug-19-21Downgrade Barclays Overweight → Equal Weight
Aug-06-21Downgrade Deutsche Bank Buy → Hold
Apr-20-21Initiated Deutsche Bank Buy
Apr-14-21Upgrade Barclays Equal Weight → Overweight
Feb-23-21Upgrade BofA Securities Underperform → Neutral $93 → $94
Feb-19-21Upgrade Raymond James Mkt Perform → Outperform
Feb-11-21Downgrade Citigroup Buy → Neutral
Jan-19-21Upgrade Morgan Stanley Equal-Weight → Overweight $159 → $129
Nov-19-20Initiated Maxim Group Buy $170
Oct-21-20Downgrade Goldman Neutral → Sell
Aug-25-20Downgrade Jefferies Buy → Hold
Aug-24-20Downgrade H.C. Wainwright Buy → Neutral $270 → $123
Aug-19-20Upgrade Citigroup Neutral → Buy
Aug-19-20Downgrade Barclays Overweight → Equal Weight
Jul-10-20Downgrade Stifel Buy → Hold $298 → $193
Mar-30-20Upgrade Jefferies Hold → Buy $232
Mar-18-20Upgrade RBC Capital Mkts Underperform → Sector Perform $175 → $157
Feb-25-20Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-24-20Downgrade BofA/Merrill Neutral → Underperform
May-16-22 09:40AM  
May-11-22 09:47AM  
May-09-22 03:30PM  
May-06-22 04:01PM  
May-05-22 04:01PM  
Apr-28-22 09:40AM  
Apr-26-22 04:01PM  
Apr-04-22 09:10AM  
Mar-28-22 02:01AM  
Mar-24-22 04:17PM  
Mar-18-22 05:01PM  
Feb-24-22 04:01PM  
Feb-03-22 04:01PM  
Feb-02-22 04:01PM  
Jan-27-22 06:07PM  
Jan-26-22 06:01PM  
Jan-18-22 04:01PM  
Jan-14-22 11:42AM  
Jan-13-22 04:01PM  
Jan-06-22 09:30AM  
Dec-24-21 12:38AM  
Dec-18-21 12:38AM  
Dec-03-21 04:01PM  
Nov-22-21 04:01PM  
Nov-15-21 10:45AM  
Nov-05-21 02:01PM  
Nov-04-21 05:01PM  
Oct-25-21 09:56PM  
Oct-05-21 01:08PM  
Oct-04-21 04:01PM  
Sep-20-21 04:01PM  
Sep-17-21 07:15AM  
Aug-31-21 09:03AM  
Aug-30-21 04:01PM  
Aug-07-21 01:00AM  
Aug-05-21 04:01PM  
Jul-21-21 05:29AM  
Jul-15-21 04:20PM  
Jul-14-21 04:01PM  
Jul-10-21 05:10AM  
Jun-22-21 04:01PM  
Jun-07-21 04:01PM  
Jun-04-21 01:01AM  
May-27-21 04:01PM  
May-18-21 04:01PM  
May-07-21 08:00PM  
May-06-21 04:01PM  
May-04-21 04:01PM  
Apr-30-21 04:01PM  
Apr-23-21 12:01AM  
Apr-08-21 04:01PM  
Mar-25-21 04:01PM  
Mar-24-21 04:01PM  
Mar-19-21 05:01PM  
Mar-16-21 09:10PM  
Mar-14-21 10:38PM  
Mar-12-21 04:55AM  
Mar-10-21 09:45PM  
Mar-07-21 01:13PM  
Mar-04-21 08:12AM  
Mar-03-21 04:15PM  
Feb-23-21 06:55AM  
Feb-22-21 02:20PM  
Feb-20-21 06:15PM  
Feb-19-21 06:30PM  
Feb-18-21 04:01PM  
Feb-15-21 10:00PM  
Feb-13-21 03:00PM  
Feb-11-21 03:28PM  
Feb-10-21 02:52PM  
Feb-09-21 04:01PM  
Jan-21-21 02:08AM  
Jan-12-21 11:54AM  
Jan-11-21 04:01PM  
Jan-06-21 09:30AM  
Jan-05-21 12:15PM  
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.A r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.